Loyal CEO Celine Halioua on FDA-approved longevity drugs for dogs — and what it means for humans

Summary

Loyal, founded by CEO Celine Halioua, is developing drugs explicitly targeting lifespan extension in dogs — a regulatory and commercial wedge into longevity science that no company had previously pursued through an FDA approval pathway. The company has already secured the first-ever efficacy approval for a longevity drug and established the first regulatory pathway for a lifespan-extension indication across any species. A pivotal, FDA-enabling clinical trial on dog lifespan is currently underway.

The Science

Loyal's lead program targets the IGF-1 and growth hormone axis. Large-breed dogs — Newfoundlands, Great Danes — maintain abnormally elevated growth hormone levels into adulthood, accelerating cellular turnover and compressing lifespan. The drug suppresses those levels to ranges naturally seen in mid-sized breeds, effectively slowing biological aging. The mechanism is well-validated across species, from worms to mice, and certain human centenarians carry analogous genetic profiles to long-lived small-breed dogs like chihuahuas.

A second drug in development targets metabolic fitness in senior dogs — analogous to how Metformin or intermittent fasting works — but is explicitly engineered to avoid appetite suppression, a commercial non-starter in the pet market. Loyal currently has four drugs in development.

The Business Case

Developing a dog drug costs $20–50 million and takes four to seven years. The human equivalent runs approximately $1 billion and over a decade. That cost and time compression, combined with a pet market where owner willingness to pay is extreme and largely uncorrelated with income, makes canine longevity commercially viable in a way human longevity drugs are not yet.

Generic drugs repurposed for novel veterinary indications can receive 10 years of exclusivity from the FDA — solving the off-patent trap that undermines investment in drugs like Metformin or aspirin for human longevity. Halioua points out that aspirin may have genuine longevity benefit, but no company will spend the required capital to prove it when the compound is freely genericized.

Halioua has received unsolicited offers of up to $50,000 from individual dog owners seeking access to the drug pre-approval — offers she declined and flagged voluntarily to the FDA.

Regulatory and Political Tailwinds

The current U.S. administration is described as actively pro-longevity, which Halioua views as a potential accelerant on the human drug side, where the regulatory environment remains more complex. The veterinary FDA is stringent but incentive-aligned: preventative medicine already dominates successful pet drug categories, from heartworm prevention to flea and tick treatments.

AI in Drug Development

Loyal has no AI story, and Halioua is direct about why. The datasets required to model drug interactions and long-term biological outcomes simply do not exist yet. AlphaFold-style breakthroughs solve a fraction of the drug development problem; the dominant risks in Loyal's current lifespan trial are operational — data quality, veterinarian compliance, and dog dropout rates. She sees narrow utility in early-stage AI tools like Chai Discovery for antibody binding design, but views clinical-side AI as premature given the absence of foundational biological datasets.

Loyal is actively building biobanks that could become one of the most comprehensive translational aging datasets in any species, positioning the company for future data-driven research without overpromising on current AI applicability.

Operations and Outlook

Loyal operates fully remote, with significant team concentrations in St. Louis, Kansas, and Florida, prioritizing best-fit hiring over geographic proximity to San Francisco. Halioua describes the company's next major milestone as bringing the first drug to market, which she targets within approximately the next year. The company has raised from Valor Equity Partners, among others. It remains private, with no public indication of IPO timing.